Top Markets
#1 Black Phoenix Black Phoenix +195.62%
#2 Islamic Coin Islamic Coin +158.04%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +28.16%
#5 Acurast Acurast +25.86%
#6 Cryptopia Cryptopia +21.79%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +17.72%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 wojak wojak +14.13%
#10 Playnance Playnance +13.71%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
ARYx Therapeutics, Inc. ARYx Therapeutics, Inc.

ARYx Therapeutics, Inc.

ARYX
Kedudukan dalam Saham #41545
Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc.... Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. ATI-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.
Harga Saham
$0.0005
Disegerakkan terakhir: 2026-08-11
Modal Pasaran
$16.73K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan ARYx Therapeutics, Inc. (ARYX)

Kategori

Healthcare
Pendapatan untuk ARYx Therapeutics, Inc. (ARYX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini ARYx Therapeutics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi ARYx Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
$1.76B -
IN